ProSomnus, Inc. (NASDAQ: OSA), a pioneer in non-CPAP Obstructive Sleep Apnea (OSA) therapy, has revealed that its precision oral appliance therapy (OAT) devices effectively treat OSA, according to ...

Sept. 14, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), today announced that their precision sleep ...

PLEASANTON, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), the leading non-CPAP Obstructive Sleep Apnea Therapy, today ...

ProSomnus, Inc. (NASDAQ: OSA) is set to feature its precision sleep apnea devices in upcoming medical conferences, showcasing new data on the efficacy, safety and effectiveness of ProSomnus ...

PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy ...

ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision oral appliance therapy (OAT) for the treatment of Obstructive Sleep Apnea (OSA), today announced that its ProSomnus EVO ...

Jan. 29, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ) (the“Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapyTM, announced that the company is well-positioned to ...

ProSomnus is honored to partner with Lovell to expand access to Precision Oral Appliance Therapy for the millions of Veterans with Obstructive Sleep Apnea.” — Len Liptak, CEO, ProSomnus Sleep ...

“ProSomnus delivered another record setting quarter further establishing ProSomnus as the leading non-CPAP therapy for Obstructive Sleep Apnea. An estimated 3 to 5 million people have OSA, have ...

Scientific Abstracts and Presentations Feature New and Additional Data Demonstrating the Efficacy, Effectiveness, and Safety of ProSomnus Precision Devices for the Treatment of Obstructive Sleep Apnea ...